Creative BioMart Biomarker provides customers with prostate-specific membrane antigen (PSMA) immunohistochemical analysis services. Customers only need to provide tissue samples (the primary antibodies used can be provided by the customer or by us), and we will return detailed experimental data, pictures and reports. Our services are only used for research purposes and not for clinical diagnosis.
|
PSMA Testing |
| Analyte: |
PSMA |
| Synonyms: |
prostate-specific membrane antigen, glutamate carboxypeptidase II, GCPII, N-acetyl-L-aspartyl-L-glutamate peptidase I, NAALADase I, NAAG peptidase |
| Sample Type: |
tissue sample |
| Assay Platform: |
immunohistochemical (IHC) analysis |
| Biomarker Application Area: |
prostate cancer |
| * Perform three replicate tests on each sample, and include appropriate controls in each assay. |
Figure 1. Molecular structure of PSMA (Tateishi, et al. 2020)
Assay Background
PSMA is a type II membrane glycoprotein, composed of intracellular domain, transmembrane domain and extracellular domain. PSMA has unique folate hydrolase and neurocarboxypeptidase activities. PSMA is expressed in tissues such as prostate, small intestine, salivary glands, and proximal renal tubules, and the expression level in prostate is higher than other tissues. PSMA is a well-established and highly specific prostate epithelial cell membrane antigen, which is highly expressed in almost all prostate cancers. Its expression level is correlated with tumor aggressiveness, disease recurrence and metastatic disease. Therefore, PSMA is considered as a specific biomarker of prostate cancer, which has research significance in the progression of prostate cancer and is also an ideal target for prostate cancer imaging and treatment. In addition, PSMA is not expressed in the normal vascular system, but is expressed in the neovascular system of solid tumors (such as pancreatic cancer, kidney cancer, lung cancer and bladder cancer), so it is also considered to be the target of these tumor treatment research.
Workflow of PSMA Detection at Creative BioMart Biomarker
Customers provide: tissue samples, primary antibodies (antibodies can also be provided or purchased by our company).
We provide: remaining primary antibodies and samples or test materials (paraffin-embedded tissue sample, section, etc.), complete experimental reports (including experimental raw data, experimental pictures, experimental procedures, instrument and reagent information, and professional result analysis).
Why Choose Creative BioMart Biomarker for PSMA Detection Service?
- High quality and reliable IHC analysis service
The IHC analysis services provided by Creative BioMart Biomarkers include the processing of tissue samples, paraffin embedding, sectioning, staining, antibody incubation, counterstaining, dehydration, mounting, and microscopic imaging. Customers can also discuss experimental schemes with our experts.
- Experienced experts team
Our experts have extensive experience in biomarker testing, and will perform each test in full accordance with standard experimental operating procedures to ensure that the test results delivered are accurate and repeatable.
- Fast testing and reasonable price
We have been committed to providing customers with efficient services to ensure that the experimental results are delivered within the predetermined time. Our testing services have reasonable and competitive prices in the industry, which can help customers reduce research costs.
If you are interested in our services, please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Akhtar, T. H.; et al. Prostate-specific membrane antigen-based therapeutics. Advances in Urology. 2012, 2012: 973820.
- Bouchelouche, K.; et al. Prostate specific membrane antigen-a target for imaging and therapy with radionuclides. Discovery Medicine.2010, 9(44): 55-61.
- Tateishi, U. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Japanese Journal of Clinical Oncology. 2020, 50(4): 349-356.
